Cancer combination therapy and recombinant vectors
AssigneeTocagen Inc.
InventorsJoan M. Robbins, Douglas J. Jolly, Derek G. Ostertag, Tiffany Huang, Harry E. Gruber
Life of this patent
Estimating the term…
Loading patent…
AssigneeTocagen Inc.
InventorsJoan M. Robbins, Douglas J. Jolly, Derek G. Ostertag, Tiffany Huang, Harry E. Gruber
Estimating the term…
This disclosure relates to a combination therapy of chemotherapeutics and/or radiosensitizing agents with a replication competent viral vectors for treating cell proliferative disorders and chemotherapeutic treatments. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.
A method of treating a cancer, said method comprising administering to the cancer a replication competent mammalian oncoretroviral vector containing a therapeutic cassette, the therapeutic cassette comprising a gene encoding a polypeptide having prodrug-activating activity, wherein the vector infects the cancer cells and wherein the cancer cells expresses the gene encoding the polypeptide;
A method of treating a cancer in a subject, comprising administering to the subject that is free of any chemotherapeutic agents a replication competent mammalian oncoretroviral vector containing a therapeutic cassette, the therapeutic cassette comprising a gene encoding a polypeptide having cytosine deaminase activity, allowing the vector to infect cancer cells of the cancer and spread, wherein the cancer cells expresses the gene encoding the polypeptide;
Dependencies are inferred from the claim text.